Universe Pharmaceuticals INC income statement UPC
In fiscal 2025, which ended Sep 30, 2025, Universe Pharmaceuticals INC reported revenue of $17.9 billion, down 22.4% from the year before. It recorded a net loss of $3.7 billion. The operating loss came to $2.9 billion, an operating margin of -16.3%. Diluted earnings per share were -$8.06. Across the 5 fiscal years shown, revenue grew from $48.0 million in fiscal 2021 to $17.9 billion in fiscal 2025, about 339.2% a year.
USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.
| Line |
FY 2025
Sep 30, 2025
|
FY 2024
Sep 30, 2024
|
FY 2023
Sep 30, 2023
|
FY 2022
Sep 30, 2022
|
FY 2021
Sep 30, 2021
|
|---|---|---|---|---|---|
| Revenue |
17,859
-22.4%
|
23,024
-28.7%
|
32,309
+80383.8%
|
40
-16.3%
|
48
|
| Cost of revenue |
11,558
-31.8%
|
16,953
-22.9%
|
21,994
+120400.9%
|
18
-19.4%
|
23
|
| Gross profit |
6,301
+3.8%
|
6,072
-41.1%
|
10,315
+47019.7%
|
22
-13.6%
|
25
|
| Research and development |
672
-77.8%
|
3,031
-37.6%
|
4,859
+63457.2%
|
8
+39.9%
|
5
|
| Selling, general and administrative |
8,545
-22.7%
|
11,061
+17.4%
|
9,423
+44207.9%
|
21
+239.2%
|
6
|
| Operating expenses |
9,217
-34.6%
|
14,092
-1.3%
|
14,281
|
—
|
12
|
| Operating income |
-2,916
+63.6%
|
-8,020
-102.2%
|
-3,966
|
—
|
14
|
| Other income (expense) |
-756
-650.5%
|
-101
|
—
|
—
|
—
|
| Pretax income |
-3,672
+54.8%
|
-8,121
-87.7%
|
-4,327
-60898.6%
|
-7
-151.9%
|
14
|
| Income tax |
—
|
607
-73.1%
|
2,254
+276305.3%
|
1
-65.4%
|
2
|
| Net income |
-3,672
+57.9%
|
-8,727
-32.6%
|
-6,581
-83102.6%
|
-8
|
—
|
| Basic EPS |
-8.06
+98.7%
|
-626.96
+42.4%
|
-1,089.21
+16.8%
|
-1,309.11
|
—
|
| Diluted EPS |
-8.06
+98.7%
|
-626.96
+42.4%
|
-1,089.21
+16.8%
|
-1,309.11
|
—
|
| Weighted average shares, basic |
0
+3174.9%
|
0
+130.4%
|
0
+0.0%
|
0
|
—
|
| Weighted average shares, diluted |
0
+3174.9%
|
0
+130.4%
|
0
+0.0%
|
0
|
—
|
| Other measures | |||||
| Depreciation and amortization |
517
+6.5%
|
486
-4.5%
|
509
+95187.2%
|
1
+19.5%
|
0
|
| EBITDA |
-2,398
+68.2%
|
-7,534
-117.9%
|
-3,457
|
—
|
14
|
| Interest coverage |
-12.57x
|
-28.83x
|
—
|
—
|
—
|
| Margins | |||||
| Gross margin |
35.28%
|
26.37%
|
31.93%
|
54.53%
|
52.78%
|
| Operating margin |
-16.33%
|
-34.83%
|
-12.28%
|
—
|
28.32%
|
| Pretax margin |
-20.56%
|
-35.27%
|
-13.39%
|
-17.67%
|
28.51%
|
| Profit margin |
-20.56%
|
-37.90%
|
-20.37%
|
-19.70%
|
—
|
| EBITDA margin |
-13.43%
|
-32.72%
|
-10.70%
|
—
|
29.25%
|
| Effective tax rate |
—
|
—
|
—
|
—
|
17.24%
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. More on our methodology.
New to this? Read How to Read an Income Statement, With a Real Example.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- UPC (Nasdaq)
- Fiscal year ends
- September 30
- Incorporated in
- China
- Headquarters
- Ji'An, Jiangxi, China
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 1809616
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.